More Than Just Sticky: The Fluid Dynamics of Implantation
The primary mechanism of HETM is its influence on the viscosity of the transfer medium. Computational fluid dynamics simulations (n=1 simulation study, 2018) demonstrate that increasing viscosity to match intrauterine fluid properties (approximately 0.5 mg/mL HA) enhances fundal embryo retention. This prevents the 'cervical displacement' of the embryo often caused by the withdrawal of the transfer catheter, effectively anchoring the embryo in the optimal implantation zone.
Beyond physical viscosity, hyaluronan serves as a biological ligand. It interacts with CD44 receptors on the blastocyst and endometrium, potentially facilitating the initial 'tethering' phase of implantation. However, the exact molecular weight of the HA used in commercial formulations varies, and its role in modulating the local immune environment remains a frontier area of research.
A Tale of Two Meta-Analyses
The scientific record is currently split. On one hand, a 2022 Cochrane review (n=3,215) supported the use of HETM, showing a clear live birth benefit (RR 1.22). On the other, a 2026 meta-analysis (n=4,063) found the effect disappeared when high-risk trials were excluded (RR 1.06, CI 0.85–1.31). This discrepancy suggests that the perceived benefit of HA may be heavily influenced by the quality of trial design and the baseline success rates of the clinics involved.
A critical secondary finding is the increased risk of multiple pregnancies. The RR of 1.49 suggests that HA might enhance the survival or implantation of lower-quality embryos that would otherwise fail, or potentially increase the risk of monozygotic twinning, though data on the latter remains inconclusive. This presents a clinical dilemma for practitioners aiming for strict single embryo transfer (SET) protocols.
The Add-On Economy
From a health economics perspective, HETM represents a significant out-of-pocket cost for patients. Regulatory bodies in Australia and the UK have raised concerns that these 'add-ons' are marketed ahead of definitive evidence. Health technology assessments (HTAs) are currently impeded by 'poor trial design' and 'inconsistent outcome reporting' in the commercial sector.
Despite these warnings, the use of HETM continues to expand into specialized niches, including PGT-A cycles and frozen-thawed embryo transfers (FET). In propensity-matched FET cycles, success rates were notably higher (60.6% vs 47.5%), suggesting that the cryopreservation process might leave embryos more reliant on external adherence support than fresh embryos.